1-Days In-Person Seminar

Cannabinoids as Drugs -- Where do we stand today?

Loren Gelber
Oct 31 - Oct 31 , 2019

Starting at


Oct 31 - Oct 31 , 2019
Buy Now

This seminar will cover the latest information about Cannabinoids as Drugs.  It will start with an in-depth review of the recent FDA hearing on Cannabinoids and discuss the various reactions to it.  The approval of Epidiolex will be discussed, as will recent FDA Warning Letters to some companies who market cannabidiol (CBD) on the internet.

Some of the recent postings about CBD, cannabis terpenes and other similar substances will be used to consider whether FDA attention is warranted.  The current state of research on cannabinoids as drugs will be discussed.  Claims for CBD which have been made on past and current websites, current legal standing and actions and the state of the cannabinoid market will be reviewed.  This discussion may also be useful to those investing in cannabis market stocks or those considering doing so.


Anyone currently marketing Cannabinoids or considering doing so would benefit from attending this seminar.  It would also be useful for those who might have products that compete with them.  Investors considering the cannabis market will also benefit.  Questions, comments and general discussion will be encouraged.

  • CEOs and Future Product Selectors
  • Marketing
  • Investors
  • Pharmaceutical Chemists
  • 1.       FDA 5/30/19 Cannabinoids Meeting

a.       Meeting Structure and Panel Members

b.      Summary of Presentations

c.       After-Meeting Reactions

d.      Docket

  • 2.       Epidiolex

a.       Studies for approval

b.      Strategies for approval

c.       Labeling

d.      Current market

  • 3.       FDA Warning Letters re CBD websites

a.       Curaleaf

b.      Advanced Spine and Pain

c.       Nutra Pure

d.      Pot Network Holdings

  • 4.       Current Cannabinoid Research

a.       ClinicalTrials.gov

b.      Press Releases

  • 5.       Recent web postings re Cannabinoids

a.       Claims

b.      Legal Status

c.       Business

d.      Stock Market

e.      Hemp or Marijuana?

  • 6.       Discussion and Questions
Seminar (Price/Register)
Oct 31 - Oct 31 , 2019 (1 Days) Durham,NC

Single Attendee

Seminar Fee Includes:
AM-PM Tea/Coffee
Seminar Material
Attendance Certificate
$100 Gift Cert for next seminar

Other Registration Option
  1. Download the Order Form
  2. Fill this form with attendee details & payment details
  3. Fax your PO to 1-888-883-7697 or,
  4. Email it to cs@compliance.world

Payment Mode

By Check -

Pay your check issued from the payee to "Redstone Learning Inc." (Our Parent Company) and mail the check to –
Compliance.world (Redstone Learning Inc.)
1180 Avenue of the Americas,
8th Floor, New York,
NY 10036

  Media Partners

If you wish to partner with us for this event

please contact us: partner or
call us: 1-866-978-0800

Media Partner Benefits

  • Logo and company data on the event website.
  • Logo on the conference material distributed during the conference.
  • Media Partner’s brochure distributed along with conference material.
  • Logo on all the mailings before and after the event.
  • 10% discount to media partner's subscribers.

Media Partner to do

  • Banner (min 728x90 or 468x60) on the Media Partner website.
  • Insertion of the event in the event calendar, both printed and/or online.
  • Announcement article of the conference on the Magazine and/or Website.
  • Dedicated email blast to all subscribers of Media Partner.
  • Article on the Magazine and/or Website after the conference.


If you wish to partner with us for this event

please contact us: sponsor@compliance.world or
call us: 1-866-978-0800
Speaker: Loren Gelber, Regulatory Compliance Consultant (Ex-FDA Official)

Dr. Loren Gelber has more than 40 years of experience in pharmaceutical industry regulatory compliance. She worked for about 10 years at the FDA, including as a reviewer in the Division of Generic Drugs. She participated in the development of method validation requirements for HPLC analytical methods. She then transitions to industry, working for four different pharmaceutical companies. For the last 13 years she has been a regulatory compliance consultant, both for consulting companies and independently.

Follow us

Toll Free